A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Trial Details

NCT ID

NCT06361888

Phase

PHASE2 / PHASE3

Sponsor

Hutchmed

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
• Nab-paclitaxel Plus Gemcitabine
• Surufatinib with Nab-paclitaxel, and Gemcitabine

Locations (sample)

• Hefei, Anhui, China|31.86389,117.28083
• Beijing, Beijing Municipality, China|39.9075,116.39723
• Chongqing, Chongqing Municipality, China|29.56026,106.55771
• Fuzhou, Fujian, China|26.06139,119.30611
• Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

• Fully understand and voluntarily sign an informed consent form, willing and able to follow the study process;
• Age range is 18-75 years old (inclusive);
• Pancreatic cancer confirmed by histology or cytology;
• Stage IV metastasis Pancreatic cancer patients;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.